Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Advancing Regulatory Science

Advancing Regulatory Science

                        Regulatory Science Extramural Research and Development Projects
          Advancing Regulatory Science News and Upcoming Events
          Centers of Excellence in Regulatory Science and Innovation (CERSIs)
          Past News and Events - Advancing Regulatory Science


                        Focus Areas of Regulatory Science Report Home
          Science & Research
          Science and Research Special Topics
          Advancing Regulatory Science
          FDA Center/Office Regulatory Science Research Priority Areas for CERSI ProgramAdvancing Regulatory Science FDA Center/Office Regulatory Science Research Priority Areas for CERSI Program
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFDA has identified the following priority areas for Center of Excellence in Regulatory Science and Innovation (CERSI) research, based on the Agency’s current unmet regulatory science needs. This list will be updated periodically as FDA’s needs change.

**High-priority topics, with needs across product lifecycle and relevant demographic groups (including but not limited to sex, gender, age, race, ethnicity, geography and analysis of difference between groups, where applicable):**

	Tobacco, including, but not limited to toxicity, addiction, health effects, behavior, and communications. See link on CTP research priorities for more information.
		Advance development of individualized therapies
		Reducing healthcare-associated infection:
		Developing better understanding of the effectiveness of sterilization and reprocessing of medical devices
			Further developing pathogen-reduction technologies for whole blood and blood components
			Promoting development of innovative antimicrobial approaches
		Issues related to opioid use, misuse, and dependence
		Oncology, addressing key scientific questions that arise during regulatory review. See link on OCE Scientific Collaborative for more information
		Facilitating development of medical products to address the COVID-19 pandemic (diagnostics, therapeutics, vaccines, and products subject to EUAs/EUA expansion for the treatment, prevention, or diagnosis of COVID-19)
		Evaluating digital health technologies such as consumer-grade wearables to better measure patient experience living with disease and with medical products and AI/ML algorithm data sets.
	**Develop and evaluate methods to improve quality and safety of FDA-regulated products for use by patients and consumers, including methods to improve predictive value of nonclinical evaluation**
	Methodologies for development, manufacturing/quality control of complex generic drugs, biosimilars, biological products, and medical devices
		Biocompatibility and biological risk evaluation of medical devices and their component materials
		Evaluation of innovative methods such as:
		Microphysiological systems (MPS) (organs on a chip)
			Computer modeling and simulation (e.g., in silico clinical trials and biocompatibility modeling)
			Discovery and validation of minimally invasive biomarkers, particularly for diseases and medical states, where few markers exist (such as traumatic brain injury), including predictive microbiome biomarkers and use of current methods such as EEG and bio-imaging.
	**Develop methods and tools to improve and streamline clinical and postmarket evaluation of FDA-regulated products, including**
	Scientifically valid approaches to incorporating patient input (e.g., patient preference, patient reported outcomes) into regulatory decision-making
		Complex, adaptive, Bayesian, and other novel clinical trial designs
		Approaches to leveraging large, complex data to inform regulatory decision-making, including use of “real world” data sources and mobile technologies
		Evaluation of product safety and efficacy in special populations, including but not limited to pregnant individuals, lactating individuals, perinatal, pediatric, racial and ethnic minorities and older adults
		Inclusive demographic evaluations including but not limited to, age, sex, gender, race and ethnicity, and geography including analysis of:
		Safety and efficacy (e.g., analysis of sex, racial and ethnic differences in product safety)
			Effective comprehension and usability of FDA communications
			Global and US based clinical trial participation
		Develop and evaluate shared decision-making tools to better enable patients to make fully informed decisions about their use of medical devices. These tools may be created for priority areas such as dermal fillers, breast implants, or opioid use disorder devices.See links on Office of Women's Health (OWH) Research Roadmap and Office of Minority Health and Health Equity (OMHHE) Research and Collaboration Program for more information.

                                                                                  Content current as of:
      07/28/2021
              
              
Topic(s)
			  Training & EducationAdvancing Regulatory Science

          
                        Regulatory Science Extramural Research and Development Projects
          Advancing Regulatory Science News and Upcoming Events
          Centers of Excellence in Regulatory Science and Innovation (CERSIs)
          Past News and Events - Advancing Regulatory Science


                        Focus Areas of Regulatory Science Report
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop